-
Innovative bispecific antibody YKST02 officially started Phase I clinical trial
On May 21, 2024, Excyte Biopharma Ltd. officially launched the Phase I clinical trial of YKST02, a bispecific antibody drug for treating relapsed/refractory multiple myeloma, in Beijing.Prof. Chen Wen
2024/06/17 admin 735
-
First in human (FIH) dosing completed for YKST02, a bispecific antibody drug for multiple myeloma immunotherapy in Phase I clinical trial
On June 14, 2024, the FIH dosing safely completed in the Phase I clinical trial of YKST02 (anti-CD3×BCMA), a bispecific antibody drug independently developed by Excyte Biopharma Ltd. (Excyte), for the
2024/06/17 admin 296
-
The IND application for YKST02 has been approved, and Phase I clinical trials will start soon
On April 30, 2024, YKST02, an innovative bispecific antibody developed by Excyte Biopharma Ltd, officially received IND approval from the Center for Drug Evaluation of NMPA. YKST02 targets BCMA and CD
2024/05/21 admin 414
-
The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
On April 8, 2024, the signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held in Beijing between Excyte Biopharma Ltd. (hereinafter referred to as &q
2024/04/22 admin 407
-
NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration
NHL/ALL免疫治療候選雙抗藥物YK012 I期臨床試驗(yàn)完成首例受試者給藥 2023年5月24日,，益科思特（北京）醫(yī)藥科技發(fā)展有限公司開發(fā)的用于治療復(fù)發(fā)/難治性B細(xì)胞非霍奇金淋巴瘤的雙特異性抗體藥物YK012（CD3×CD19）I期臨床研究在中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院I期病房完成首例給藥,。當(dāng)日上午9:40,，YK012注射液通過微量注射泵及輸注管路緩緩流入受試者體內(nèi),，至給藥后24h，受試者無
2023/06/07 admin 345
-
NHL/ALL immunotherapy candidate dual antibody drug YK012 has officially entered the phase I clinical trial phase
NHL/ALL免疫治療候選雙抗藥物YK012 正式進(jìn)入I期臨床試驗(yàn)階段2023年5月8日,，益科思特（北京）醫(yī)藥科技發(fā)展有限公司開發(fā)的用于治療復(fù)發(fā)性/難治性B細(xì)胞非霍奇金淋巴瘤的雙特異性抗體藥物YK012（CD3×CD19）I期臨床研究在京正式啟動(dòng),。5月9日,，首例受試者順利簽署知情同意書。中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院臨床研究中心副院長,、腫瘤內(nèi)科主任石遠(yuǎn)凱教授（左2）,，益科思特（北京）醫(yī)藥科技發(fā)
2023/06/07 admin 293
